Definigen

The company provides human iPSC-derived cell models and AI-driven phenomics services for drug discovery and safety assessment. They offer specialized products like hepatocytes, stellate cells, and organoids, alongside automated cell painting and high-content imaging to generate predictive biological insights. Their platform serves global biopharmaceutical companies by modeling diseases such as MASLD and Alpha-1 antitrypsin deficiency to optimize lead selection and anticipate translational outcomes.